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OBJECTIVES We sought to determine the factors associated with long-term survival in patients with
primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion.
BACKGROUND Epoprostenol improves survival in patients with PPH in New York Heart Association
(NYHA) functional class III or IV. However, some patients do not benefit from epoprostenol
and must be considered for lung transplantation. The best timing for listing these patients on
a lung transplantation program is currently unknown.
METHODS Between December 1992 and January 2001, 178 patients with PPH in NYHA functional
class III or IV were treated with epoprostenol. The 6-min walk test (WT) and right-sided
heart catheterization were performed at baseline, after three months on epoprostenol and
thereafter once a year.
RESULTS Overall survival rates at one, two, three, and five years were 85%, 70%, 63%, and 55%,
respectively. On univariate analysis, the baseline variables associated with a poor outcome
were a history of right-sided heart failure, NYHA functional class IV, 6-min WT 250 m
(median value), right atrial pressure 12 mm Hg, and mean pulmonary artery pressure 65
mm Hg. On multivariate analysis, including both baseline variables and those measured after
three months on epoprostenol, a history of right-sided heart failure, persistence of NYHA
functional class III or IV at three months, and the absence of a fall in total pulmonary
resistance of 30%, relative to baseline, were associated with poor survival.
CONCLUSIONS Survival of patients with PPH treated with epoprostenol depends on the severity at baseline,
as well as the three-month response to therapy. These findings suggest that lung transplan-
tation should be considered in a subset of patients who remain in NYHA functional class III
or IV or in those who cannot achieve a significant hemodynamic improvement after three
months of epoprostenol therapy, or both. (J Am Coll Cardiol 2002;40:780–8) © 2002 by
the American College of Cardiology Foundation
Primary pulmonary hypertension (PPH) is an uncommon
disorder of unknown etiology, characterized by a progressive
increase in pulmonary artery pressure (PAP) and pulmonary
vascular resistance, often leading to right ventricular failure
and death, especially in patients in New York Heart
Association (NYHA) functional class III or IV (1–3).
In the national North American Registry of 194 patients
with PPH, the median survival was 2.8 years (2). Most
patients included in the registry received conventional ther-
apy with an oral anticoagulant, diuretic, oxygen, digoxin,
and calcium channel blocker. Among the baseline hemody-
namic variables, high levels of right atrial pressure (RAP)
(20 mm Hg) and mean PAP (85 mm Hg) and a low
cardiac index (CI) (2 l/min/m2) were associated with poor
survival.
Epoprostenol (i.e., prostaglandin I2 or prostacyclin
[PGI2]) is a potent, short-acting vasodilator and inhibitor of
platelet aggregation that is produced by the vascular endo-
thelium (4). Long-term treatment with continuous intrave-
nous infusion of PGI2 (Flolan by Glaxo Smith Kline,
Brentford, UK) has been shown to improve exercise capac-
ity, hemodynamics, and quality of life in most patients with
severe PPH refractory to conventional therapy (5,6). A
significant improvement in survival with PGI2 treatment
was demonstrated in an unblinded, randomized, 12-week
study of patients with severe PPH (5). In contrast, there are
few data on the long-term survival of patients with PPH
treated with continuous intravenous PGI2, although Sha-
piro et al. (7) described significantly improved survival in a
retrospective analysis of 69 patients with PPH treated with
PGI2 over a five-year period, as compared with an historic
group of patients from the U.S. National Institutes of
Health Registry.
Initially proposed as a bridge to lung transplantation,
intravenous PGI2 is now considered as a first line therapy
and an alternative to lung transplantation in severe patients
with PPH. However, some patients with PPH do not
benefit from this therapy and in these cases the only
therapeutic option remaining is lung transplantation. There
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is a need to identify the factors that enable the early
prediction of a failure of PGI2 therapy so that these patients
may be placed on a waiting list for lung transplantation at
the earliest possible opportunity. The major objective of the
present study was to analyze the usefulness of clinical and
hemodynamic parameters that predict the outcome in
PGI2-treated patients with PPH.
METHODS
Patient group. From December 1992 to January 2001, 178
patients who were above 15 years old with severe PPH were
treated with long-term intravenous infusion of PGI2. The
diagnosis of PPH was established by standard diagnostic
criteria (1,8). All patients were classified as being in NYHA
functional class III or IV, despite optimal medical therapy,
including oral anticoagulants, diuretics, long-term oxygen,
and oral vasodilators. Exclusion criteria were as: 1) pulmo-
nary hypertension associated with connective tissue disease,
congenital heart disease, portal hypertension, or human
immunodeficiency viral infection; 2) distal chronic throm-
boembolic pulmonary hypertension; 3) chronic pulmonary
disease; and 4) an acute pulmonary vasodilator response that
predicted a clinical response to oral calcium channel block-
ers (9). An historic group of 135 patients with PPH
matched for NYHA functional class and who never received
PGI2 was used for comparative survival analysis. Data from
this control group were extracted from our personal data
base. Patients from this historic group were comparable to
those from the PGI2-treated group in terms of functional
class, exercise capacity and hemodynamics (10). This retro-
spective study was approved by our Institutional Review
Board.
Hemodynamics and exercise capacity. The baseline eval-
uation included a medical history and physical examination,
routine blood tests, a nonencouraged 6-min walk test (WT),
as previously described (11), and right-sided heart catheter-
ization using standard techniques. Acute vasodilator re-
sponsiveness was evaluated using a short-term vasodilator
challenge (inhaled nitric oxide or intravenous PGI2), as
previously described (12).
A clinical evaluation, including NYHA functional class
and 6-min WT, was done every three months. Repeated
right-sided heart catheterization was performed after three
months and one year of treatment with PGI2 and thereafter
once a year.
Treatment regimen. For each patient, venous access for
the infusion of PGI2 (Flolan) was obtained by insertion of a
permanent, tunneled Groshong catheter (Bard Access Sys-
tems, Salt Lake City, Utah) into a subclavian vein. Epopro-
stenol was infused continuously with the use of a portable
infusion pump (CADD-Plus by Sims Deltec Inc., St. Paul,
Minnesota). During the initial hospital period, patients
were trained in pump programming, drug preparation,
sterile technique, and catheter care. Epoprostenol therapy
was initiated at a dose of 1 ng/kg/min, and the dose was
increased by 1 ng/kg/min every 12 h up to 10 ng/kg/min.
After this dose was achieved, patients were discharged from
the hospital. Dose adjustments were made systematically to
reach a mean level of 14  4 ng/kg/min at three months.
Thereafter, dose adjustments were based on clinical symp-
toms consistent with clinical deterioration or the occurrence
of adverse events, distance walked during exercise testing,
and hemodynamic measurements.
Statistical analysis. Data were stored on a PC-based data
spreadsheet. Analysis was performed using the Statview
version 5.0 statistical package (SAS Institute, Cary, North
Carolina). All data are expressed as the mean value  SD.
One-way analysis of variance with repeated measures was
performed for functional and hemodynamic values obtained
at baseline, after three months and after one year of
treatment with intravenous PGI2. Multiple comparisons
were made when the F test value was statistically signif-
icant. A p value 0.05 was considered as statistically
significant. The Student t test and chi-square test for
independence were used to compare differences between
mean values and between rates measured at baseline for
patients in NYHA functional class III and those in class
IV, as appropriate.
For the survival analysis, we used the commencement of
PPH therapy (conventional or PGI2) as the start point to
determine the survival duration. The Kaplan-Meier method
was used to estimate the proportion of patients surviving at
each time point. Univariate analysis based on the propor-
tional hazards model was used to examine the relationship
between survival and selected demographic, medical history
and hemodynamic variables measured at the initial cathe-
terization and after three months of PGI2 therapy. The
results are expressed as hazard ratios with 95% confidence
intervals. For continuous variables, we chose to separate
patients into two groups on both sides of the median value.
Patients who underwent lung transplantation were consid-
ered as censored at the date of transplantation.
Multivariate analysis based on the Cox proportional
hazards regression model was used to examine the indepen-
dent effect of each variable on survival, controlling for
possible confounding variables. Two separate regressions
were performed: the first one included only baseline vari-
ables and the second one included both baseline variables
and those measured after three months of PGI2 therapy.
Abbreviations and Acronyms
CI  cardiac index
PAP  pulmonary artery pressure
NYHA  New York Heart Association
PGI2  epoprostenol (prostacyclin)
PPH  primary pulmonary hypertension
RAP  right atrial pressure
SvO2  mixed venous oxygen saturation
TPR  total pulmonary resistance
WT  walk test
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RESULTS
Baseline clinical and hemodynamic variables. The pa-
tients’ clinical characteristics, exercise capacity, and hemo-
dynamic measurements at baseline are shown in Table 1.
The frequencies of symptoms at the initiation of PGI2
therapy were as follows: 100% for dyspnea on exertion, 42%
for syncope or near syncope, and 35% for lower limb edema.
Raynaud’s phenomenon was reported by 27 patients (15%).
At baseline, the mean distance achieved in the 6-min
WT was 240  146 m (range 0 to 550 m), and the median
value was 250 m.
Long-term follow-up of patients. FUNCTIONAL CLASS
AND EXERCISE CAPACITY. Patients were followed for a
mean period of 26  21 months (range 0.5 to 98 months).
At three months, 10 patients were dead before evaluation
and 2 had undergone lung transplantation. The remaining
166 patients were evaluated according to their NYHA
functional class and 6-min WT. Their mean dose of PGI2
was 14  4 ng/kg/min (range 7 to 34 ng/kg/min). The
NYHA functional class improved in 125 patients (75%),
was unchanged in 40 patients (24%) and worsened in only 1
patient. Ninety-two patients (55%) were classified in
NYHA functional class I (n  2) or II (n  90), and 74
(45%) were in class III (n  67) or IV (n  7). The mean
increase in the 6-min walk distance was 125 m from
baseline (251  144 m at baseline to 376  114 m at 3
months; p  0.001). The 6-min WT improved in 149
patients (90%), with a mean increase of 147 m. The mean
increase in the distance walked was significantly greater for
patients who were initially in NYHA functional class IV
(222  142 m) than for patients in class III (88  99 m;
p  0.0001), but the absolute distance walked in 6 min
remained lower (326  106 m vs. 398  108 m; p 
0.0002).
At one year, 14 additional patients were dead and 11 had
undergone lung transplantation. In the 130 patients who
were evaluated, the mean dose of PGI2 was 21  7
ng/kg/min (range 8 to 40 ng/kg/min). Eighty-two patients
(63%) were classified in NYHA functional class I (n 5) or
II (n 77), and 48 patients (37%) were still in class III (n
42) or IV (n  6). In terms of NYHA functional class, 115
patients remained stable, 5 improved, and 10 worsened
between 3 and 12 months of treatment. In these 130
patients evaluated at one year, the mean increase in the
6-min WT was 142 m after three months (253  144 m to
395  107 m; p  0.001), with stabilization after one year
of treatment with PGI2 (395  112 m).
HEMODYNAMIC MEASUREMENTS. One hundred and
fifty-six patients underwent repeat right-sided heart cathe-
terization after three months of continuous PGI2 therapy,
and 107 patients had it after one year. The results of the
hemodynamic variables are summarized in Table 2. In 77
patients, a long-term evaluation was performed after 41 
17 months (16 to 96 months) of PGI2 therapy (mean dose
33  11 ng/kg/min [range 9 to 63 ng/kg/min]). In these
patients, hemodynamic improvement was sustained, with a
slight increase in the CI (2.5  0.6 l/min/m2 at one year to
2.8  0.6 liters/min per m2 at follow-up; p  0.002),
resulting in a lower level of total pulmonary resistance
(TPR) (25.3  6.9 U/m2 to 22.8  6.9 U/m2; p  0.001).
Table 1. Baseline Clinical Characteristics, Exercise Capacity, and Hemodynamics in 178











Female/male 135 /43 89 /31 46 /12
Age (yrs) 43  13 43  13 45  13
Onset of symptoms (months) 34  34 35  36 31  31
History of syncope 75 (42%) 50 (42%) 25 (43%)
History of right-sided heart failure 62 (35%) 30 (25%) 0.001 33 (57%)
Six-minute walk test (m) 240  146 308  107 0.0001 99  109
Hemodynamics
mRAP (mm Hg) 12  6 11  5 0.0001 15  6
mPAP (mm Hg) 67  14 66  13 67  13
PAOP (mm Hg) 9  3 9  3 9  4
CI (l/min/m2) 1.96  0.56 1.98  0.49 0.01 1.76  0.36
TPR (U/m2) 36.7  11.8 35.4  10.4 0.02 39.5  12.6
mSAP (mm Hg) 94  15 97  14 0.001 88  14
Heart rate (beats/min) 88  15 87  14 89  14
SvO2 (%) 54  10 56  9 0.0001 49  9
*Comparisons between New York Heart Association (NYHA) functional class (FC) III and class IV patient groups were made
using the unpaired Student t and chi-square tests, as appropriate. Data are presented as the number (%) of patients or mean value
 SD.
CI cardiac index; mPAPmean pulmonary artery pressure; mRAPmean right artrial pressure; mSAPmean systemic
artery pressure; PAOP pulmonary artery occlusion pressure; SvO2 mixed venous oxygen saturation; TPR total pulmonary
resistance.
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COMPLICATIONS. Minor complications attributable to
PGI2 were frequent and included jaw pain, headache,
diarrhea, flushing, leg pain, and nausea/vomiting. Seventy-
six episodes of catheter-related sepsis occurred in 53 patients
(0.19 catheter-related infections per patient-year). In four
patients, a severe catheter-related infection was directly
responsible for death, including three nosocomial infections
that were acquired in the intensive care unit where the
patients were hospitalized for severe right-sided heart fail-
ure. Seven patients developed severe pulmonary edema
leading to death. In these patients, a postmortem examina-
tion of the lungs demonstrated pulmonary veno-occlusive
disease or pulmonary capillary hemangiomatosis.
OUTCOME. At the time of follow-up (28  22 months), 93
patients remained on long-term PGI2 treatment (mean
follow-up 38 22 months [range 3.9 months to 8.6 years]);
27 patients had undergone lung or heart/lung transplanta-
tion after a mean period of 14 months of PGI2 therapy (1
month to 5 years); and 58 patients had died after a mean
period of 18 months of PGI2 therapy (5 days to 5.5 years).
The overall survival rates at one, two, three, and five years
were 85%, 70%, 63%, and 55%, respectively (Fig. 1).
Patients who were classified in NYHA functional class IV at
baseline had a poorer prognosis than those in class III (Fig.
2A). The estimated rates of patients surviving at one, two,
and three years were 76%, 60%, and 47% for patients in
NYHA functional class IV, as compared with 90%, 76%,
and 71% for patients in class III (p  0.001 by the log-rank
test). After three months of treatment with PGI2, patients
whose symptoms had improved such that they could be
reclassified in functional class I or II had an increased
probability of survival. In these patients, the survival rates at
one, two, and three years were 100%, 93%, and 88%,
respectively, as compared with 77%, 46%, and 33% in
patients persisting in class III or IV (Fig. 2B).
The majority of deaths (n  44; 76%) occurred during
the first two years of PGI2 therapy. The main cause of death
was progressive right-sided heart failure in 39 patients.
Other causes of death included sepsis (n  8), pulmonary
Table 2. Hemodynamic Effects of Long-Term Epoprostenol
Therapy
A: Three Months of Epoprostenol Therapy (n  156)
Baseline Three Months
mRAP (mm Hg) 13  6 11  5*
mPAP (mm Hg) 66  13 59  12†
CI (l/min/m2) 1.9  0.4 2.4  0.5†
TPR (U/m2) 36.4  11.1 25.5  6.9†
SvO2 (%) 54  9 61  9†
B: One Year of Epoprostenol Therapy (n  107)
Baseline Three Months One Year
mRAP (mm Hg) 12  5 11  5‡ 12  6
mPAP (mm Hg) 68  14 60  12§ 60  12§
CI (l/min/m2) 1.9  0.4 2.5  0.5§ 2.5  0.5§
TPR (U/m2) 37.3  10.5 25.4  6.6§ 25.0  6.9§
SvO2 (%) 55  9 63  8§ 63  10§
*p  0.017 and †p  0.0001, comparison with baseline values (analysis of variance).
Data are expressed as the mean value  SD. ‡p  0.002 and §p  0.0001,
comparison with baseline values (analysis of variance). No difference was demon-
strated between mean values measured at 3 months and those measured at one year.
Data are expressed as the mean value  SD.
Abbreviations as in Table 1.
Figure 1. Kaplan-Meier survival estimates in 178 patients with primary pulmonary hypertension (PPH) from the initiation of epoprostenol (PGI2) therapy.
For comparison, survival data are also shown for a historical control group of 135 patients with PPH matched for New York Heart Association functional
class and who never received intravenous (IV) epoprostenol therapy. In the group of patients treated with PGI2 (solid line), the overall survival rates at one,
two, three, and five years were 85%, 70%, 63%, and 55%, respectively, as compared with 58%, 43%, 33%, and 28% in the historical control group (dashed
line) (p  0.0001 by the Cox-Mantel log-rank test).
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edema (n  7), hemorrhage (n  3), and stroke (n  1).
Postmortem verification was performed in 17 patients,
revealing typical plexiform lesions (n  10), pulmonary
veno-occlusive disease (n  5), and pulmonary capillary
hemangiomatosis (n  2) (13).
Factors associated with survival. UNIVARIATE ANALYSIS.
The results of univariate analysis of the relationship between
survival and variables measured at baseline are shown in
Table 3. Mortality was not associated with patient age or
gender, the presence of Raynaud’s phenomenon, anorexi-
genic exposure, or a history of syncope. Only a history of
right-sided heart failure, baseline NYHA functional class
IV, and baseline 6-min walk distance 250 m (correspond-
ing to the median value) were associated with poor survival.
Two additional hemodynamic variables were significantly
related to an increased risk of death: mean RAP12 mm Hg
Figure 2. Survival in patients with primary pulmonary hypertension treated with intravenous epoprostenol (PGI2) according to New York Heart
Association (NYHA) functional class (FC). (A) Estimated percentages of survival for patients in NYHA FC IV at baseline (dashed line) were 76%, 60%,
and 47% at one, two, and three years, respectively, as compared with 90%, 76%, and 71% for patients in NYHA FC III at baseline (solid line) (p  0.001
by the Cox-Mantel log-rank test). (B) After three months of treatment with epoprostenol, survival rates for patients reclassified in NYHA FC I or II (solid
line) were 100%, 93%, and 88% at one, two, and three years, respectively, as compared with 77%, 46%, and 33% for patients persisting in NYHA FC III
or IV (dashed line) (p  0.0001 by the Cox-Mantel log-rank test).
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and, paradoxically, mean PAP65 mm Hg. The CI, mixed
venous oxygen saturation (SvO2), and calculated TPR were
not related to survival in this patient group.
The results of univariate analysis relating survival time to
selected variables measured after three months of treatment
with PGI2 are shown in Table 4. Persistent NYHA func-
tional class III or IV, despite PGI2 therapy, was strongly
associated with an increased risk of death (Fig. 2B), as well
as the absolute distance walked in 6 min (Fig. 3A).
Conversely, the change in the distance walked from baseline
was not a predictor of survival in this study (Fig. 3B).
Hemodynamic variables associated with better survival were
mean RAP 10 mm Hg, a paradoxical high level of mean
PAP 59 mm Hg, SvO2 62%, an increase in CI of 0.5
l/min/m2 from baseline and a decrease in TPR of 30%
relative from baseline.
MULTIVARIATE ANALYSIS. Two separate multivariate anal-
yses were performed to determine, first, the effects of
selected baseline values on survival and, second, the effects
of selected values measured both at baseline and after three
months of PGI2 therapy. In the univariate analysis of
baseline variables, three clinical variables (NYHA functional
class, history of right-sided heart failure, and 6-min walk
distance) and two hemodynamic variables (RAP and mean
PAP) were significantly related to mortality. In the multi-
variate analysis, we examined the independent effect of each
independent variable in the presence of others on mortality.
In the multivariate Cox proportional hazards regression
analysis, including baseline variables, only a history of
right-sided heart failure and RAP 12 mm Hg were
independently related to poor survival. When both baseline
and three-month variables were included in the multivariate
regression analysis, three variables remained independently
associated with mortality: a history of right-sided heart
failure, the persistence of NYHA functional class III or IV
after three months of PGI2 therapy, and the absence of a
significant fall in TPR (30% relative to baseline) after three
months of PGI2 therapy.
DISCUSSION
Our study provides new insights on the long-term outcome,
survival and prognostic factors in patients in NYHA func-
tional class III or IV who have PPH treated with continuous
intravenous PGI2. This study shows that survival is mainly
related to simple pretherapeutic clinical variables, such as
NYHA functional class and distance achieved in the 6-min
WT. In addition, both the clinical and hemodynamic
responses to PGI2 therapy in the first three months ap-
peared to be major predictors of survival in this patient
group. Indeed, patients in NYHA functional class I or II
after three months of PGI2 therapy had a markedly better
survival than did patients in class III or IV. Moreover, a
sustained hemodynamic response to PGI2, which can be
measured by the fall in pulmonary vascular resistance
after a three-month treatment period, seems to be a
major prognostic factor. Although there was no formal
control group in this study, validated historic data on
patients with PPH were available to compare the long-
term survival between patients treated with PGI2 and
those not treated (2,10,14).
Exercise capacity. The 6-min WT is a reliable tool for the
assessment of exercise capacity in patients with PPH
(5,15,16). Furthermore, it is an independent predictor of
mortality (17). In the present study, we demonstrated that
the distance achieved during the 6-min WT before starting
PGI2 therapy correlates with survival, as previously suggested







Age 44 yrs 1.17 (0.71–1.94) 0.535
Gender (female/male) 0.95 (0.53–1.71) 0.877




History of syncope (yes/no) 0.75 (0.44–1.25) 0.226
History of right-sided heart
failure (yes/no)
2.19 (1.31–3.64) 0.003
NYHA FC IV vs. III 2.24 (1.34–3.73) 0.002
Six-minute walk distance 250 m 2.20 (1.31–3.69) 0.003
Baseline hemodynamics
mRAP 12 mm Hg 2.74 (1.58–4.75) 0.0003
mPAP 65 mm Hg 1.72 (1.04–2.86) 0.036
PAOP 10 mm Hg 0.87 (0.51–1.50) 0.623
CI 1.80 l/min/m2 0.96 (0.58–1.59) 0.879
TPR 35.4 U/m2 0.65 (0.39–1.09) 0.102
mSAP 93 mm Hg 1.24 (0.71–2.18) 0.449
Heart rate 88 beats/min 0.76 (0.43–1.34) 0.349
Systolic index 21.4 ml/m2 1.46 (0.83–2.58) 0.173
SvO2 54.5% 1.54 (0.93–2.56) 0.096
Abbreviations as in Table 1.
Table 4. Univariate Analysis Relating Survival Time to Selected











Increase in distance walked
112 m from baseline
1.09 (0.61–1.96) 0.759
Dose of epoprostenol achieved
14 ng/kg/min
0.60 (0.33–1.08) 0.086
mRAP 10 mm Hg 3.57 (1.65–7.71) 0.001
mPAP 59 mm Hg 1.94 (1.06–3.55) 0.032
Decrease in mPAP 10%
relative to baseline
1.25 (0.69–2.27) 0.462
CI 2.4 l/min/m2 1.45 (0.79–2.66) 0.231
Increase in CI 0.5 l/min/m2
relative to baseline
2.35 (1.23–4.52) 0.010
TPR 25 U/m2 1.53 (0.82–2.85) 0.185
Decrease in TPR 30%
relative to baseline
1.90 (1.02–3.54) 0.041
SvO2 62% 2.64 (1.41–4.95) 0.002
Abbreviations as in Table 1.
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by Barst et al. (5). Furthermore, although the absolute value of
the 6-min WT performed after three months of PGI2 therapy
correlated with survival, its increase from baseline did not.
Survival. Long-term treatment with intravenous PGI2 im-
proves exercise capacity, hemodynamics, and survival in
most patients with PPH in NYHA functional class III or
Figure 3. (A) Kaplan-Meier survival estimates in 156 patients with primary pulmonary hypertension (PPH), according to the results of the 6-min walk test
(6’ WT) performed after three months of epoprostenol (PGI2) therapy. Survival rates for patients walking 380 m during the 6’ WT (corresponding to
the median value) (solid line) were 99%, 88%, and 81% at one, two, and three years, respectively, as compared with 86%, 64%, and 56% for patients walking
380 m (dashed line) (p  0.0005 by the Cox-Mantel log-rank test). (B) Kaplan-Meier survival estimates in 156 patients with PPH, according to the
change () in the 6’ WT between baseline and three months of PGI2 therapy. No difference in survival was demonstrated in patients who improved their
6-min walk distance to 112 m (corresponding to the median value) (solid line), as compared with those who did not (dashed line) (p  0.86 by the
Cox-Mantel log-rank test).
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IV. Despite these favorable outcomes, continuous intrave-
nous infusion of PGI2 is a far from ideal treatment of severe
pulmonary hypertension, as it is complicated, uncomfort-
able for patients and very costly. Side effects such as
flushing, headache, jaw pain, and diarrhea are common.
More important complications can occur, mainly related to
the delivery system: the incidence of catheter-related infec-
tions was 0.19 per patient-year in our study, similar to
incidences previously reported (0.1 to 0.4 per patient-year)
(5,6). Despite significant clinical improvement, hemody-
namic parameters usually remained severely compromised in
many patients on long-term PGI2 therapy. This suggests
that PGI2 given over the long term may have other effects in
addition to pulmonary vasodilation at rest, including myo-
cardial protection from ischemic injury, as well as effects on
pulmonary vascular growth and remodeling (6,18,19). Fur-
thermore, PGI2 may improve hemodynamics at exercise,
even in the absence of a significant hemodynamic change at
rest (20).
In our study, a relatively low mean PAP value (i.e., below
the median value at baseline and after three months of PGI2
therapy) was a predictor of poor survival. This finding is
counterintuitive and may be a function of random analysis
of a wide variety of variables, so that one inevitably may
produce an apparent level of significance that is not truly
justified. Moreover, mean PAP reflects only one aspect of
pulmonary hemodynamics, and one should discuss pulmo-
nary resistance (i.e., mean PAP/CI) rather than mean PAP
alone. This is clearly demonstrated in our present study,
where the reduction in TPR after three months of PGI2
therapy (30% relative to baseline) is a clear indicator of
better survival, whereas the reduction in mean PAP does not
modify the patients’ overall survival (Table 4). These inva-
sive criteria appear to provide important prognostic infor-
mation in addition to simple clinical measurements, such as
NYHA functional class and the 6-min WT. On the basis of
this information, we recommend performing a repeat inva-
sive hemodynamic procedure after a three-month period of
PGI2 treatment in these patients.
Timing for lung transplant listing. Our study provides
the basis for a rational approach to the management of
patients with severe PPH receiving long-term PGI2 infu-
sion. The current shortage of organ donors, coupled with a
five-year survival rate of only 50%, precludes systematic
listing of patients with PPH for lung or heart/lung trans-
plantation. Therefore, it is widely accepted that lung trans-
plantation should be reserved for those patients with PPH
who fail to respond to optimal medical therapy. Our current
results suggest that such a subset of patients may be
identified as those who remain in NYHA functional class
III and/or IV or who do not achieved a 30% fall, relative to
baseline, in TPR after three months of PGI2 therapy.
Conclusions. Survival of patients with PPH treated with
epoprostenol depends on the severity at baseline, as well
as the three-month response to therapy, which is evalu-
ated by both clinical measures and hemodynamics. These
findings suggest that lung transplantation should be
considered in a subset of patients who remain in NYHA
functional class III or IV or who do not achieve a
significant hemodynamic improvement after three
months of epoprostenol therapy.
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